27523 Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis (AD) from the phase 2 and phase 3 clinical trial program

2021 ◽  
Vol 85 (3) ◽  
pp. AB150
Author(s):  
Eric L. Simpson ◽  
Jonathan I. Silverberg ◽  
Audrey Nosbaum ◽  
Kevin Winthrop ◽  
Emma Guttman-Yassky ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Atopic Dermatitis ◽  
Safety Analysis ◽  
Severe Atopic Dermatitis ◽  
Phase 2 ◽  
Phase 3 ◽  
Clinical Trial Program

27082 Upadacitinib in moderate-to-severe atopic dermatitis: Combined safety analysis of phase 3 studies (Measure Up 1, Measure Up 2, and AD Up)

2021 ◽  
Vol 85 (3) ◽  
pp. AB129
Author(s):  
Emma Guttman-Yassky ◽  
Alan D. Irvine ◽  
Jonathan I. Silverberg ◽  
Kim A. Papp ◽  
Amy S. Paller ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Safety Analysis ◽  
Severe Atopic Dermatitis ◽  
Phase 3

scholarly journals Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM)

2018 ◽  
Vol 124 (1) ◽  
pp. 27-38 ◽  
Author(s):  
Janet Thomas ◽  
Harvey Levy ◽  
Stephen Amato ◽  
Jerry Vockley ◽  
Roberto Zori ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Phase 3 ◽  
Clinical Trial Program

scholarly journals Dupilumab in Moderate-to-Severe Atopic Dermatitis With or Without Comorbid Asthma: Pooled Analysis of 2 Randomized Phase 3 Trials (LIBERTY AD SOLO 1 & 2)

2018 ◽  
Vol 141 (2) ◽  
pp. AB132
Author(s):  
Mette Deleuran ◽  
Emma Guttman-Yassky ◽  
Kulli Kingo ◽  
Neil M.H. Graham ◽  
Gianluca Pirozzi ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Pooled Analysis ◽  
Severe Atopic Dermatitis ◽  
Phase 3
Sign in / Sign up

Export Citation Format

Share Document